Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Ipsen is conducting a clinical study titled An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity. The study aims to assess the safety and efficacy of IPN10200, focusing on its pharmacodynamics profile and determining the optimal dose for treating adult upper limb spasticity.
Intervention/Treatment: The study tests IPN10200, a biological intervention administered as a powder and solvent for injection. It is compared against Dysport and a placebo, with the goal of improving treatment outcomes for upper limb spasticity.
Study Design: This interventional study is randomized with a parallel intervention model. It employs quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused, aiming to find the most effective and safe dosage of IPN10200.
Study Timeline: The study began on February 3, 2021, and is currently recruiting. The latest update was submitted on August 26, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
Market Implications: The study’s outcomes could significantly impact Ipsen’s stock performance and investor sentiment, particularly if IPN10200 demonstrates superior efficacy and safety. Success in this study could position Ipsen favorably against competitors in the spasticity treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.